What does CUSIP 00973Y108 represent in this 13F holders report?

CUSIP 00973Y108 is the security identifier for AKRO - AKERO THERAPEUTICS, INC. - Common Stock used to aggregate holder disclosures.

How many institutions held AKRO - AKERO THERAPEUTICS, INC. - Common Stock in Q4 2021?

96 institutional investors reported AKRO - AKERO THERAPEUTICS, INC. - Common Stock for Q4 2021. Use the holders table for investor-level position and value details.

AKERO THERAPEUTICS, INC. - Common Stock (AKRO)

CUSIP: 00973Y108

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class: Equity / Common Stock
Shares outstanding: 82,872,659
Total 13F shares: 35,317,227
Share change: +196,842
Total reported value: $746,760,550
Price per share: $21.15
Number of holders: 96
Value change: +$3,654,957
Number of buys: 36
Number of sells: 48

Quarterly Holders Quick Answers

What is CUSIP 00973Y108?
CUSIP 00973Y108 identifies AKRO - AKERO THERAPEUTICS, INC. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2022
Previous quarter: Q3 2021

Recent filing periods for CUSIP 00973Y108:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of AKRO - AKERO THERAPEUTICS, INC. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of AKERO THERAPEUTICS, INC. - Common Stock (AKRO) as of Q4 2021

As of 31 Dec 2021, AKERO THERAPEUTICS, INC. - Common Stock (AKRO) was held by 96 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 35,317,227 shares. The largest 10 holders included Skorpios Trust, JANUS HENDERSON GROUP PLC, ALKEON CAPITAL MANAGEMENT LLC, Atlas Venture Life Science Advisors, LLC, venBio Partners LLC, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, GOLDMAN SACHS GROUP INC, Point72 Asset Management, L.P., and Redmile Group, LLC. This page lists 96 institutional shareholders reporting positions in this security for the Q4 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2021 vs Q3 2021 Across Filers

Q3 2021 holders

102

Q4 2021 holders

Holder diff

-6

Investor	Q3 2021 Shares	Q4 2021 Shares	Share Diff	Share Chg %	Q3 2021 Value $	Q4 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.